Samsung Bioepis launches denosumab biosimilars, Obodence and Xbryk in Europe: Incheon, Korea Tuesday, December 2, 2025, 14:00 Hrs [IST] Samsung Bioepis Co., Ltd. announced the lau ...

A pair of biosimilar companies have launched their copies of a big-selling monoclonal antibody used to treat various bone ...

OBODENCE (60 mg pre-filled syringe) and XBRYK (120 mg vial) become available across Europe as of December 2025 and January 2026, respectively Marks Samsung Bioepis' 10th and 11th biosimilars ...

Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), ...

Samsung Bioepis Co., Ltd. today announced the launch of OBODENCEtm (60 mg pre-filled syringe) and XBRYKtm (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be ...

Israel’s Teva Pharmaceutical Industries has announced that the European Commission (EC) has granted marketing authorizations ...

National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec One biotech will receive a year of laboratory and office s ...

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. announced that the European Commission (EC) has granted marketing authorizations for its two denosumab ...

Dr. Reddy's Laboratories has secured European Commission marketing approval for AVT03, a biosimilar to Prolia and Xgeva, used ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

LAKE ZURICH, Ill., October 29, 2025--(BUSINESS WIRE)--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced ...

The FDA has approved two new drugs that are biosimilars to denosumab, adding to the ever-expanding field of less expensive options of the popular anti-osteoporosis and cancer-related bone loss drug; ...